Business Context and Reporting Period
This Form 8-K Current Report was filed by Genprex, Inc. on June 27, 2023. The filing reports on the results of the Company's 2023 Annual Meeting of Stockholders held on the same date and provides updates on clinical trials and manufacturing for its lead oncology drug candidate, REQORSA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events and operational updates rather than financial performance data.
Material Changes and Corporate Actions
- Director Elections: Stockholders elected Jose Antonio Moreno Toscano and J. Rodney Varner as Class III directors to serve until the 2026 annual meeting.
- Accounting Firm Ratification: Stockholders approved the ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Compensation Policy Update: The Board adopted an Amended and Restated Outside Director Compensation Policy, adding Restricted Stock Units (RSUs) as a potential annual equity award for independent directors.
Clinical Trial and Manufacturing Updates
Acclaim-1 (REQORSA + Tagrisso for NSCLC)
The Safety Review Committee approved advancement to the Phase 2 expansion portion. The recommended Phase 2 dose is 0.12 mg/kg. The Company expects to dose the first patient in the third quarter of 2023, pending the transition to a new lipid nanoparticle (LNP) contract development and manufacturing organization (CDMO).
Acclaim-2 (REQORSA + Keytruda for NSCLC)
The Company is currently enrolling patients in the Phase 1 dose escalation portion. Completion of this portion is expected by the first quarter of 2024. Delays are attributed to slower-than-anticipated enrollment, competition from other studies, and the transition to a new LNP CDMO.
Acclaim-3 (REQORSA + Tecentriq for ES-SCLC)
The Company expects to enroll the first patient in the third quarter of 2023. Delays are similarly linked to the transition to a new LNP CDMO and manufacturing timelines.
Manufacturing and Supply Chain
The Company estimates sufficient REQORSA supply to treat current patients through approximately September 2023. Failure to produce a new batch by this time could delay clinical trials. The Company is transitioning from "REQORSA 1.0" to "REQORSA 2.0" to improve scalability, stability, and shelf life, while consolidating CDMOs.
Investor Verification Checklist
- Verify the timeline for the transition to the new LNP CDMO and its impact on the projected Q3 2023 patient dosing for Acclaim-1 and Acclaim-3.
- Confirm the status of REQORSA manufacturing batches to ensure supply continuity beyond September 2023.
- Monitor enrollment rates for the Acclaim-2 trial given the noted competition and slower-than-anticipated pace.
- Review the specific terms of the new Outside Director Compensation Policy regarding RSU grants.